Export as PDF
Cohort Acronym
PPMI

Cohort type
Neurodegenerative disease-specific cohort

Disease
Parkinson's disease

Participant type
At-risk diagnosis, Condition diagnosed, No diagnosis

Profile
Recruitment Period 2010 - present 
Sample size at start or planned sample size if still recruiting  
Estimated Current Sample Size  
Age at Recruitment    
Gender Male and Female 
Abstract

The Parkinson’s Progression Marker Initiative (PPMI) is an observational, international study designed to establish biomarker defined cohorts and identify clinical, imaging, genetic and biospecimen Parkinson’s disease (PD) progression markers to accelerate disease modifying therapeutic trials. A total of 423 untreated PD, 196 Healthy Control (HC), 64 SWEDD (scans without evidence of dopaminergic deficit) subjects, and 65 Prodromal subjects (individuals with hyposmia or REM Sleep Behavior Disorder) were enrolled. PPMI is actively enrolling affected and unaffected individuals with genetic mutations in LRRK2, GBA, or SNCA through the end of 2018. For the most up to date enrollment numbers, please visit http://www.ppmi-info.org/study-design/study-cohorts/. To enroll PD subjects as early as possible following diagnosis, subjects were eligible with only asymmetric bradykinesia or tremor plus a dopamine transporter (DAT) binding deficit on SPECT imaging. Acquisition of data was standardized as detailed at www.ppmi-info.org.

 
Country Australia, Austria, France, Germany, Greece, Israel, Italy, Norway, Spain, United Kingdom, USA 
Contact details
Institution name Institute for Neurodegenerative Disorders 
Website http://www.ppmi-info.org/ 
Principal Investiator (PI) Ken Marek, MD 
Contact email ppmi@michaeljfox.org 
Contact phone number 212-509-0995 
Address Institute for Neurodegenerative Disorders 
Funders (Core support) The Michael J. Fox Foundation for Parkinson's Research, Abbvie, Allergan, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol-Myers Squibb, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, and Golub Capital 

Variables Collected

Brain related measures: N/A
Funtional rating: Individual physiological, Individual psychological
Anthropometric: Blood pressure, Height, Weight
Physical: Cardiovascular, Hearing and Vision, Musculoskeletal, Reproductive, Respiratory
Biological samples: Blood, Cerebral spinal fluid (CSF), Other, Urine
Genotyping: Gene screening
Brain imaging: Magnetic resonance imaging (MRI), Single photon emission computerised tomography (SPECT)
Brain banking: N/A
Lifestyle: Alcohol, Dietary habits, Physical activity, Smoking
Socio-economic: Education, Ethnic group, Family circumstances
Health service utilisation: N/A
 
Export as PDF